Publications by authors named "Javier Medel Rebollo"
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury.
Pablo V Escribá Ángel M Gil-Agudo Joan Vidal Samsó Judith Sánchez-Raya Sebastián Salvador-de la Barrera Javier Medel Rebollo
Spinal Cord
August 2024
Article Synopsis
- Double-blind, randomized, placebo-controlled phase IIA trial tested the safety and pain relief efficacy of NFX-88 in chronic spinal cord injury (SCI) patients.
- A total of 61 adults with varying levels of SCI participated, receiving either a placebo or one of three NFX-88 doses alongside pregabalin.
- Results showed no severe side effects and indicated that the 2.1g/day dose of NFX-88 provided the most significant reduction in neuropathic pain, suggesting its potential for future trials.